The Asia-Pacific bears over half of the global cardiovascular-kidney-liver-metabolic disease burden, and its trajectory is projected to worsen by 2050 due to a rising proportion of upstream metabolic conditions like CKD, MASLD, T2DM, and obesity.
Answers are grounded in this paper and cite their sources.
Asia-Pacific CKLM burden remains disproportionately high with rising metabolic drivers projected; leaves open targeted prevention trials in this population.
Cardiovascular disease (CVD) is the leading cause of death worldwide, with the Asia-Pacific region bearing over half of this burden. The cardiovascular-kidney-liver-metabolic (CKLM) framework unifies the interrelated conditions of cardiovascular disease (CVD), chronic kidney disease (CKD), metabolic dysfunction-associated steatotic liver disease (MASLD), type 2 diabetes mellitus (T2DM) and obesity, which synergistically contribute to heightened cardiovascular risk. However, the combined CKLM burden in the region has not been characterised. Using the Global Burden of Disease Study 2023, we examined mortality and disability-adjusted life years (DALYs) of CKLM diseases across 39 Asia-Pacific countries from 1990 to 2023, with forecasts to 2050. The CKLM burden was organized into metabolic antecedents (comprising CKD, MASLD, T2DM and obesity) and downstream atherosclerotic CVD (comprising ischemic heart disease, stroke, aortic aneurysm, and peripheral artery disease). In 2023, the Asia-Pacific recorded 286.9 million CKLM-related DALYs (53.2% of global burden), with an age-standardised DALY rate of 6390.9 per 100,000 population. From 1990 to 2023, crude DALYs rose by 78.7%, outpacing the global trends (61.1%), while age-standardised DALYs fell by 25.0% - driven by improvements in atherosclerotic CVD (-35.2%) but counterbalanced by a 20.4% rise in metabolic antecedents. By 2050, age-standardised DALY rates are projected to show a 7.0% point-estimate increase regionally against an estimated 14.9% global decline, with metabolic antecedents likely to expand from 29.9% to 36.2% of the total burden between 2026 and 2050. Intraregional disparities exist across sociodemographic strata, subregions, and age-sex categories. Risk-deleted analyses identify high systolic blood pressure, high fasting plasma glucose, and dietary risks as the highest-yield modifiable targets. The worsening Asia-Pacific CKLM trajectory is decoupling from improving global trends, driven by a compositional shift from atherosclerotic CVD toward upstream metabolic antecedents. Integrated interventions addressing multiple key modifiable risks are needed.
No takes yet. Share an insight, caveat, or question.
Nagarajan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: